Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2′-deoxyuridine, 5-iodo-3′-fluoro-2′,3′-dideoxyuridine, and 3′-fluorothymidine for molecular radiotherapy of cancer: Synthesis and biological evaluation

Journal of Medicinal Chemistry

Volumn 55, Issue 6, 2012, Pages 2649-2671

  Kortylewicz, Zbigniew P ^a   Kimura, Yu ^a   Inoue, Kotaro ^a   MacK, Elizabeth ^a   Baranowska Kortylewicz, Janina ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUORO 5 IODO 2',3' DIDEOXYURIDINE; 5 IODO 3 O CYCLO (3 METHYLSALIGENYL) 2 DEOXYURIDINE MONOPHOSPHATE; 5 IODO 3 O CYCLO(3 METHYLSALIGENYL) 2 DEOXYURIDINE; 5 IODO 3 O CYCLOSALIGENYL 2 DEOXYURIDINE MONOPHOSPHATE; 5 IODO 3' O (CYCLO 3,5 DI(TERT BUTYL) 6 FLUOROSALIGENYL) 2' DEOXYURIDINE MONOPHOSPHATE; 5 IODO 3'O [CYCLO 3,5 DI(TERT BUTYL) 6 FLUOROSALIGENYL] 2' DEOXYURIDINE MONOPHOSPHATE; 5 IODO 5 O [CYCLO 3,5 DI(TERT BUTYL) 6 FLUOROSALIGENYL] 2 DEOXYURIDINE MONOPHOSPHATE; 5 IODO 5' O [CYCLO 3,5 DI (TERT BUTYL) 6 FLUOROSALIGENYL] 3' FLUORO 2',3' DIDEOXYURIDINE; 5 IODO 5' O [CYCLO 3,5 DI (TERT BUTYL) 6 FLUOROSALIGENYL] 3' FLUORO 2',3' DIDEOXYURIDINE MONOPHOSPHATE; 5 IODO 5' O [CYCLO 3,5 DI(TERT BUTYL) 6 FLUOROSALIGENYL] 2' DEOXYURIDINE MONOPHOSPHATE; 5 IODO 5' O CYCLO(3 METHYLSALIGENYL) 2' DEOXYURIDINE MONOPHOSPHATE; 5 IODO 5' O CYCLO(3 METHYLSALIGENYL) 2'DEOXYURIDINE MONOPHOSPHATE; 5 IODO 5' O CYCLOSALIGENYL 2' DEOXYURIDINE MONOPHOSPHATE; 5' O [CYCLO 3,5 DI(TERT BUTYL) 6 FLUOROSALIGENYL] 3' DEOXY 3'FLUOROTHYMIDINE MONOPHOSPHATE; 5' O [CYCLO 3,5 DI(TERT BUTYL) 6 FLUOROSALIGENYL]THYMIDINE MONOPHOSPHATE; ANTINEOPLASTIC AGENT; CHOLINESTERASE; IODINE 125; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; CANCER CELL; CANCER RADIOTHERAPY; CELL KILLING; CELL NUCLEUS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG PURITY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ISOTOPE LABELING; LETHAL DOSE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOCHEMISTRY;

BUTYRYLCHOLINESTERASE; CELL LINE, TUMOR; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLIOBLASTOMA; HUMANS; HYDROLYSIS; IODINE RADIOISOTOPES; MOLECULAR TARGETED THERAPY; NEOPLASMS; OVARIAN NEOPLASMS; RADIOPHARMACEUTICALS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE MONOPHOSPHATE; URIDINE MONOPHOSPHATE;

EID: 84858738652     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201482p     Document Type: Article

References (82)

1. Charlton, D. E. The range of high LET effects from 125I decays Radiat. Res. 1986, 107, 163-171 (Pubitemid 16048738)
2. 125I atoms not bound to DNA Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med. 1980, 37, 547-554 (Pubitemid 10105374)
3. Hofer, K. G.; Hughes, W. L. Radiotoxicity of intranuclear tritium, 125 iodine and 131 iodine Radiat. Res. 1971, 47, 94-101
4. Krisch, R. E.; Ley, R. D. Induction of lethality and DNA breakage by the decay of iodine-125 in bacteriophage T4 Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med. 1974, 25, 21-30
5. 125I incorporated into mammalian DNA Proc. Natl. Acad. Sci. U.S.A. 1974, 71, 4836-4838
6. Schmidt, A.; Hotz, G. The occurrence of double-strand breaks in coliphage T1-DNA by iodine-125 decay Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med. 1973, 24, 307-313
7. 125I Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med. 1988, 53, 353-365 (Pubitemid 18080831)
8. Lobachevsky, P. N.; Martin, R. F. Iodine-125 decay in a synthetic oligodeoxynucleotide. I. Fragment size distribution and evaluation of breakage probability Radiat. Res. 2000, 153, 263-270 (Pubitemid 30224840)
9. 123IUdR correlates with experimental in vitro cell killing effectiveness Radiat. Prot. Dosim. 2002, 99, 81-82
10. Hofer, K. G.; Keough, G.; Smith, J. M. Biological toxicity of Auger emitters: molecular fragmentation versus electron irradiation Curr. Top. Radiat. Res. Q. 1978, 12, 335-354
11. 125I compared with that of densely ionising alpha-particles Lancet 1989, 2, 650-653 (Pubitemid 19220228)
12. 125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters Nature 1977, 265, 620-621 (Pubitemid 8034083)
13. Coderre, J. A.; Packer, S.; Fairchild, R. G.; Greenberg, D.; Laster, B.; Micca, P.; Fand, I. Iodothiouracil as a melanoma localizing agent J. Nucl. Med. 1986, 27, 1157-1164
14. 125I]iodo-2′-deoxyuridine Radiat. Res. 1989, 118, 532-544 (Pubitemid 19159483)
15. 125IUdR and other radiolabelled thymidine precursors in resistant tumours Br. J. Radiol. 1991, 64, 45-49
16. 125I]iodo- 2′-deoxyuridine in the treatment of colorectal cancer metastatic to the liver J. Nucl. Med. 1996, 37, 25S-29S (Pubitemid 126701172)
17. 125I]iodo-2′-deoxyuridine Radiat. Res. 1989, 118, 532-544 (Pubitemid 19159483)
18. 125I] iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts Int. J. Cancer. 2004, 110, 145-149 (Pubitemid 38507215)
19. Sahu, S. K.; Kortylewicz, Z. P.; Baranowska-Kortylewicz, J.; Taube, R. A.; Adelstein, S. J.; Kassis, A. I. Strand breaks after the decay of iodine-125 in proximity to plasmid pBR322 DNA Radiat. Res. 1997, 147, 401-408 (Pubitemid 27150369)
20. 125I-iodoHoechst 33258 Int. J. Radiat. Biol. 2004, 80, 915-920 (Pubitemid 40138155)
21. Kullberg, E. B.; Stenerlöw, B.; Ghirmai, S.; Lundqvist, H.; Malmström, P. U.; Orlova, A.; Tolmachev, V.; Gedda, L. An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay Int. J. Oncol. 2005, 27, 1355-1360
22. Woo, D. V.; Li, D. R.; Brady, L. W.; Emrich, J.; Mattis, J.; Steplewski, Z. Auger electron damage induced by radioiodinated iodine-125 monoclonal antibodies Front. Radiat. Ther. Oncol. 1990, 24, 64-68
23. Adelstein, S. J.; Kassis, A. I.; Baranowska-Kortylewicz, J.; van den Abbeele, A. D.; Mariani, G.; Ito, S. Potential for tumor therapy with iodine-125 labeled immunoglobulins Int. J. Rad. Appl. Instrum., Part B 1991, 18, 43-44
24. 125I- labelled internalized and non-internalized monoclonal antibodies in nude mice with human colon carcinoma xenografts Nucl. Med. Biol. 1993, 20, 133-144 (Pubitemid 23043066)
25. 131I-labeled CO17-1A in a human colorectal cancer model Int. J. Cancer 1998, 76, 738-748 (Pubitemid 28243949)
26. Michel, R. B.; Castillo, M. E.; Andrews, P. M.; Mattes, M. J. In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons Clin. Cancer Res. 2004, 10, 5957-5966 (Pubitemid 39180978)
27. 125I radioimmunotherapy of small-volume peritoneal carcinomatosis J. Nucl. Med. 2009, 50, 2033-2041
28. Bloomer, W. D.; McLaughlin, W. H.; Milius, R. A.; Weichselbaum, R. R.; Adelstein, S. J. Estrogen receptor-mediated cytotoxicity using iodine-125 J. Cell. Biochem. 1983, 21, 39-45 (Pubitemid 13003423)
29. Anderson, R. E.; Holt, J. A. Binding of radiolabeled estrogens by human cells in vitro: implications to the development of a new diagnostic and therapeutic modality in the treatment of malignancies with estrogen receptors Gynecol. Oncol. 1989, 34, 80-83 (Pubitemid 19187968)
30. DeSombre, E. R.; Shafii, B.; Hanson, R. N.; Kuivanen, P. C.; Hughes, A. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose Cancer Res. 1992, 52, 5752-5758
31. 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy Nucl. Med. Biol. 2006, 33, 773-783 (Pubitemid 44247737)
32. 125I]histamine complex. Preliminary report Nucl. Med. Rev. Cent. East. Eur. 2004, 7, 113-116 (Pubitemid 40124976)
33. van Hagen, P. M.; Breeman, W. A.; Bernard, H. F.; Schaar, M.; Mooij, C. M.; Srinivasan, A.; Schmidt, M. A.; Krenning, E. P.; de Jong, M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy Int. J. Cancer 2000, 90, 186-198
34. 125I-iodo-2- methyl-1,4-naphthoquinol bis(diammonium phosphate) as a potential radio-halogenated anti-cancer agent: in vitro investigations and possible clinical implications Eur. J. Nucl. Med. 1982, 7, 115-120 (Pubitemid 12180104)
35. 125I]meta-iodobenzylguanidine Int. J. Radiat. Oncol., Biol., Phys. 1998, 41, 425-432 (Pubitemid 28243557)
36. Towu, E.; Boxer, G.; Begent, R.; Zweit, J.; Spitz, L.; Hobbs, K.; Winslet, M. In-vitro uptake of radioactive lipiodol I-131 and I-125 by hepatoblastoma: implications for targeted radiotherapy Pediatr. Surg. Int. 2001, 17, 609-613 (Pubitemid 33139429)
37. 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle J. Biomed. Nanotechnol. 2010, 6, 153-157
38. Mak, S.; Till, J. E. Use of I-125-labeled 5-iodo-2′-deoxyuridine for the measurement of DNA synthesis in mammalian cells in vitro Can. J. Biochem. Physiol. 1963, 41, 2343-2351
39. Bonmassar, E.; Houchens, D. P.; Fioretti, M. C.; Goldin, A. Uptake of 5-iododeoxyuridine as a measure of tumor growth and tumor inhibition Chemotherapy 1975, 21, 321-329
40. Feinendegen, L. E.; Henneberg, P.; Tisljar-Lentulis, G. DNA strand breakage and repair in human kidney cells after exposure to incorporated iodine-125 and cobalt-60 gamma-rays Curr. Top. Radiat. Res. Q. 1978, 12, 436-452
41. Hofer, K. G.; Keough, G.; Smith, J. M. Biological toxicity of Auger emitters: molecular fragmentation versus electron irradiation Curr. Top. Radiat. Res. Q. 1978, 12, 335-354
42. Narra, V. R.; Howell, R. W.; Harapanhalli, R. S.; Sastry, K. S.; Rao, D. V. Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design J. Nucl. Med. 1992, 33, 2196-2201
43. Bagshawe, K. D.; Boden, J.; Boxer, G. M.; Britton, D. W.; Green, A.; Partridge, T.; Pedley, B.; Sharma, S.; Southall, P. A cytotoxic DNA precursor is taken up selectively by human cancer xenografts Br. J. Cancer 1987, 55, 299-302 (Pubitemid 17036844)
44. 125I]iodo- 2′-deoxyuridine injected intratumorally in patients with breast cancer Ann. N.Y. Acad. Sci. 1993, 698, 204-211 (Pubitemid 24027644)
45. Mariani, G.; Cei, A.; Collecchi, P.; Baranowska-Kortylewicz, J.; Van den Abbeele, A. D.; Di Luca, L.; Di Stefano, R.; Viacava, P.; Ferdeghini, E. M.; Di Sacco, S. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo- 2′-deoxyuridine following intratumoral injection in patients with colorectal cancer J. Nucl. Med. 1993, 34, 1175-1183 (Pubitemid 23191339)
46. Bloomer, W. D.; Adelstein, S. J. Therapeutic application of iodine-125 labeled iododeoxyuridine in an early ascites tumour model Curr. Top. Radiat. Res. Q. 1978, 12, 513-525
47. Baranowska-Kortylewicz, J.; Kortylewicz, Z. P.; Hoffman, D.; Dalrymple, G. V. Prodrugs in site-selective delivery of radiopharmaceuticals Q. J. Nucl. Med. 1997, 41, 127-139 (Pubitemid 27261311)
48. Baranowska-Kortylewicz, J.; Kortylewicz, Z. P.; Hoffman, D.; Winoto, A.; Lai, J.; Dalrymple, G. V. Colon-specific prodrugs of 5-radioiodo-2′- deoxyuridine Acta Oncol. 1996, 35, 959-964
49. Baranowska-Kortylewicz, J.; Adelstein, S. J.; Kassis, A. I. 5-Iodo-2′-deoxyuridine-protein conjugates: synthesis and enzymatic degradation Sel. Cancer. Ther 1990, 6, 1-13 (Pubitemid 20164110)
50. 125I]IUDR-T101 antibody conjugate Cancer Biother. Radiopharm. 1999, 14, 91-98 (Pubitemid 29217788)
51. Chi, K. H.; Wang, H. E.; Chen, F. D.; Chao, Y.; Liu, R. S.; Chou, S. L.; Wang, Y. S.; Yen, S. H. Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model J. Nucl. Med. 2001, 42, 345-351 (Pubitemid 32153741)
52. Mester, J.; DeGoeij, K.; Sluyser, M. Modulation of [5-125-I] iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors Eur. J. Cancer 1996, 32A, 1603-1608 (Pubitemid 26279131)
53. Greene, R. F.; Collins, J. M. Effects of leucovorin on idoxuridine cytotoxicity and DNA incorporation Cancer Res. 1990, 50, 6652-6656 (Pubitemid 20348795)
54. Benson, A. B.; Trump, D. L.; Cummings, K. B.; Fischer, P. H. Modulation of 5-iodo-2′-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines Biochem. Pharmacol. 1985, 34, 3925-3931 (Pubitemid 16195465)
55. Kortylewicz, Z. P.; Nearman, J.; Baranowska-Kortylewicz, J. Radiolabeled 5-iodo-3′- O -(17beta-succinyl-5alpha-androstan-3-one)-2′- deoxyuridine and its 5′-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation J. Med. Chem. 2009, 52, 5124-5143
56. Meier, C.; De Clercq, E.; Balzarini, J. Nucleotide delivery from cyclosaligenyl-3′-azido-3′-deoxythymidine monophosphates (cycloSal-AZTMP) Eur. J. Org. Chem. 1998, 837-846 (Pubitemid 128534931)
57. Meier, C.; Knispel, T.; Mrquez, V. E.; Siddiqui, M. A.; De Clercq, E.; Balzarini, J. cycloSal-pronucleotides of 2′-fluoro- ara-and 2′-fluoro- ribo- 2′,3′-dideoxyadenosine as a strategy to bypass a metabolic blockade J. Med. Chem. 1999, 42, 1615-1624 (Pubitemid 29226731)
58. Ducho, C.; Wendicke, S.; Görbig, U.; Balzarini, J.; Meier, C. 3,5-Di-(tert- butyl)-6-fluoro-cycloSal-d4TMP: a pronucleotide with a considerably improved masking group Eur. J. Org. Chem. 2003, 4786-4791
59. Meier, C. cycloSal-pronucleotides: design of the concept, chemistry, and antiviral activity Adv. Antiviral Drug Des. 2004, 4, 147-213
60. Meier, C.; Meerbach, A.; Balzarini, J. cycloSal-pronucleotides: development of first and second generation chemical Trojan horses for antiviral chemotherapy Front. Biosci. 2004, 9, 873-890 (Pubitemid 39043759)
61. Ducho, C.; Görbig, U.; Jessel, S.; Gisch, N.; Balzarini, J.; Meier, C. Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides J. Med. Chem. 2007, 50, 1335-1346 (Pubitemid 46496332)
62. Meier, C. cycloSal-phosphates as Trojan horses for intracellular nucleotide and glycosylmonophosphate delivery: chemistry meets biology Eur. J. Org. Chem. 2006, 1081-1102
63. Weissner, A.; Carroll, M. L.; Green, K. E.; Kerwar, S. S.; Picket, W. C.; Schaub, R. E.; Torley, L. W.; Wrenn, S.; Kohler, C. A. Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor J. Med. Chem. 1992, 35, 1650-1662
64. van Boom, J.; Burges, P. Use of levulinic acid in the protection of oligonucleotides via the modified phosphotriester method: synthesis of decarbonucleotide U-A-U-A-U-A-U-A-UA Tetrahedron Lett. 1976, 21, 4875-4678
65. Baranowska-Kortylewicz, J.; Helseth, L. D.; Lai, J.; Schneideman, M. H.; Schneiderman, G. S.; Dalrymple, G. V. Radiolabeling kit/generator for 5-radiohalogenated uridines J. Labelled Compd. Radiopharm. 1994, 34, 513-521
66. Gisch, N.; Balzarini, J.; Meier, C. Studies on enzyme-cleavable dialkoxymethyl-cyclosaligenyl-2′,3′-dideoxy-2′, 3′-didehydrothymidine monophosphates J. Med. Chem. 2008, 51, 6752-6760
67. Meier, C. cycloSal-pronucleotides-design of chemical Trojan horses Mini- Rev. Med. Chem. 2002, 2, 219-234
68. Bazarini, J.; Aquaro, S.; Knispel, T.; Rampazzo, C.; Banchi, V.; Perno, C.; De Clercq, E.; Meier, C. Cyclosaligenyl-2′,3′-didehydro- 2′,3′-dideoxythymididne monophosphate: efficient intracellular delivery of d4TMP Mol. Pharmacol. 2000, 58, 928-935
69. Lomp, A.; Meier, C.; Hererich, M.; Wutzler, P. Evidence for cyclophosphate formation during hydrolysis of 3-methyl-cycloSal-PCVMP Nucleosides Nucleotides 1999, 18, 943-944
70. Ducho, C.; Balzarini, J.; Naesens, L.; De Clercq, E.; Meier, C. Aryl-substituted and benzo-annulated cycloSal-derivatives of 2′,3′-didehydrothymidine monophosphate: correlation of structure, hydrolysis properties and anti-HIV activity Antiviral Chem. Chemother. 2000, 13, 129-141 (Pubitemid 36733671)
71. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95
72. Meier, C.; Ducho, C.; Görbig, U.; Esnouf, R.; Balzarini, J. Interactions of cycloSal-pronucleotides with chlolinesterases from different orgins. A structure-activity relationship J. Med. Chem. 2004, 47, 2839-2852 (Pubitemid 38656737)
73. Pontén, J.; Macintyre, E. H. Long term culture of normal and neoplastic human glia Acta Pathol. Microbiol. Scand. 1968, 74, 465-486
74. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes Radiat. Res. 1987, 109, 78-89 (Pubitemid 17026116)
75. Howell, R. W.; Rao, D. V.; Hou, D. Y.; Narra, V. R.; Sastry, K. S. The question of relative biological effectiveness and quality factor for Auger emitters incorporated into proliferating mammalian cells Radiat. Res. 1991, 128, 282-292
76. Sharma, Ch. V. M; Reddy, Ch. G.; Krishna, P. R. Zirconium(IV) chloride catalyzed new and efficient protocol for the selective cleavage of p -methoxybenzyl ethers J. Org. Chem. 2003, 68, 4574-4575 (Pubitemid 36622759)
77. Aerschot, A. V.; Herdewijn, J.; Balzarini, J.; Pauwels, M.; De Clereq, E. 3′-Fluoro-2′,3′-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2′- and 3′-fluorinated 2′,3′-dideoxynucleoside analoques J. Med. Chem. 1989, 32, 1743-1749 (Pubitemid 19204355)
78. 18F]fluoro-thymidine with 2,3′-anhydro-5′- O -(4,4′-dimethoxytrityl)-thymidine J. Labelled Compd. Radiopharm. 2000, 43, 1211-1218
79. Karnovsky, M. J.; Roots, L. A "direct-coloring" thiocholine method for cholinesterases J. Histochem. Cytochem. 1964, 12, 219-221
80. Altamirano, C. V.; Bartels, C. F.; Lockridge, O. The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme J. Neurochem. 2000, 74, 869-877 (Pubitemid 30053761)
81. Thermo Scientific. Instructions. NE-PER Nuclear and Cytoplasmic Extraction Reagents. http://www.piercenet.com/instructions/2160872.pdf (accessed October 07, 2011).
82. QIAGEN Genomic DNA Handbook. www.qiagen.com/literature/render.aspx?id=405 (accessed October 07, 2011).